HIV-1 protease inhibitors and mechanisms of HIV-1's resistance.

IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Global health & medicine Pub Date : 2024-12-31 DOI:10.35772/ghm.2024.01073
Debananda Das
{"title":"HIV-1 protease inhibitors and mechanisms of HIV-1's resistance.","authors":"Debananda Das","doi":"10.35772/ghm.2024.01073","DOIUrl":null,"url":null,"abstract":"<p><p>Current anti-HIV drugs have significantly improved the prognosis of HIV infected patients so much so that it is now considered a chronic disease, and adherence to medications keeps non-detectable amounts of the virus in the body. However, HIV is still able to generate drug resistance substitutions. Protease inhibitors (PIs) in combination with other classes of anti-HIV drugs constitute an important part of the anti-HIV drug regimen. This article discusses some of the common resistance substitutions against PIs, mechanistic insight on resistance, and potential new inhibitors that can show efficacy against current resistant variants.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"357-362"},"PeriodicalIF":1.9000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680448/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global health & medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35772/ghm.2024.01073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Current anti-HIV drugs have significantly improved the prognosis of HIV infected patients so much so that it is now considered a chronic disease, and adherence to medications keeps non-detectable amounts of the virus in the body. However, HIV is still able to generate drug resistance substitutions. Protease inhibitors (PIs) in combination with other classes of anti-HIV drugs constitute an important part of the anti-HIV drug regimen. This article discusses some of the common resistance substitutions against PIs, mechanistic insight on resistance, and potential new inhibitors that can show efficacy against current resistant variants.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
HIV-1蛋白酶抑制剂和HIV-1耐药机制
目前的抗艾滋病毒药物已经显著改善了艾滋病毒感染者的预后,以至于它现在被认为是一种慢性疾病,坚持服用药物会使体内的病毒数量无法检测到。然而,艾滋病毒仍然能够产生耐药替代品。蛋白酶抑制剂(PIs)与其他类型的抗hiv药物联合使用是抗hiv药物方案的重要组成部分。本文讨论了一些针对pi的常见耐药替代品,耐药性的机制见解,以及可能对当前耐药变体有效的潜在新抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
7.70%
发文量
0
期刊最新文献
HIV-1 protease inhibitors and mechanisms of HIV-1's resistance. Imaging of unicentric hyaline-vascular variant of Castleman disease: Emphasis on perilesional fat stranding and fatty proliferation. Increase in the number of female doctors and the challenges that Japan's medical system must face. Patient-specific brain fluorodeoxyglucose positron emission tomography can detect the first effects of combination antiretroviral therapy in patient with HIV infection. Prevalence of physical frailty and its associated factors among elderly patients undergoing hepatobiliary pancreatic surgery in China.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1